1166827-55-9

Basic information

• Product Name: 3,5-dimethyl-6-[4-(trans-4-{2-[(methylsulfonyl)amino]-2-oxoethyl}cyclohexyl)phenyl]pyrazine-2-carboxamide
• CAS NO: 1166827-55-9
• Molecular Weight: 444.555
• Mol File: 1166827-55-9.mol

Chemical Properties

• CAS DataBase Reference: 3,5-dimethyl-6-[4-(trans-4-{2-[(methylsulfonyl)amino]-2-oxoethyl}cyclohexyl)phenyl]pyrazine-2-carboxamide(CAS DataBase Reference)
• NIST Chemistry Reference: 3,5-dimethyl-6-[4-(trans-4-{2-[(methylsulfonyl)amino]-2-oxoethyl}cyclohexyl)phenyl]pyrazine-2-carboxamide(1166827-55-9)
• EPA Substance Registry System: 3,5-dimethyl-6-[4-(trans-4-{2-[(methylsulfonyl)amino]-2-oxoethyl}cyclohexyl)phenyl]pyrazine-2-carboxamide(1166827-55-9)

Safety Data

• Hazardous Substances Data: 1166827-55-9(Hazardous Substances Data)

Upstream product

• 1166827-47-9 ethyl 6-{4-[trans-4-(2-tert-butoxy-2-oxoethyl)cyclohexyl]phenyl}-3,5-dimethylpyrazine-2-carboxylate 
• 1166827-45-7 tert-butyl {trans-4-[4-(6-carbamoyl-3,5-dimethylpyrazin-2-yl)phenyl]cyclohexyl}acetate 
• 1166827-46-8 6-{4-[trans-4-(2-tert-butoxy-2-oxoethyl)cyclohexyl]phenyl}-3,5-dimethylpyrazine-2-carboxylic acid 
• 1166831-68-0 methyl 2-((1s,4s)-4-(4-(6-carbamoyl-3,5-dimethylpyrazin-2-yl)phenyl)cyclohexyl)acetate 
• 1166827-53-7 tert-butyl [trans-4-(4-{[(trifluoromethyl)sulfonyl]oxy}phenyl)cyclohexyl]acetate 
• 1166827-54-8 tert-butyl {trans-4-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]cyclohexyl}acetate 
• 1166827-52-6 tert-butyl [trans-4-(4-hydroxyphenyl)cyclohexyl]acetate 
• 1166827-51-5 tert-butyl [4-(4-hydroxyphenyl)cyclohexylidene]acetate 
• 1166831-64-6 ethyl 6-hydroxy-3,5-dimethyl-1,4-dihydropyrazine-2-carboxylate 
• 1166827-49-1 ethyl 3,5-dimethyl-6-oxo-1,6-dihydropyrazine-2-carboxylate 
• 1166827-48-0 ethyl 6-chloro-3,5-dimethylpyrazine-2-carboxylate 
• 1166828-19-8 6-chloro-3,5-dimethylpyrazine-2-carboxamide 

Relevant articles and documents

CARBAMOYL COMPOUNDS AS DGAT1 INHIBITORS 190

DGAT-1 inhibitor compounds of formula (I), pharmaceutically-acceptable salts and pro- drugs thereof are described, together with pharmaceutical compositions, processes for making them and their use in treating, for example, obesity wherein, for example, Ring A is optionally substituted 2,6-pyrazindiyl; X is =O; Ring B is optionally substituted 1,4-phenylene; Y1 is a direct bond or -O-; Y2 is -(CH 2) r- wherein r is 2 or 3; n is 0 or n is 1 when Y1 is a direct bond between Ring B and Ring C and when Ring B is 1,4-phenylene and Ring C is (4-6C)cycloalkane; Ring C is optionally substituted (4-6C)cycloalkane, (7-10C)bicycloalkane, (8-12C)tricycloalkane, phenylene or pryidindiyl; L is a direct bond or -O-; p is 0, 1 or 2 and when p is 1 or 2 RA1 and RA2 are each independently hydrogen or (1-4C)alkyl; Z is carboxy or a mimic or bioisostere thereof.